Chu, L. C., Wang, Z. J., Kambadakone, A., Hecht, E. M., He, J., Narang, A. K., Laheru, D. A., Arif-Tiwari, H., Bhosale, P., Bolan, C. W., Brook, O. R., Bezuidenhout, A. F., Do, R. K. G., Galgano, S. J., Goenka, A. H., Guimaraes, A. R., Hough, D. M., Kulkarni, N., Le, O., … Zaheer, A. (2022). Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of abdominal radiology disease focus panel on PDAC. Abdominal Radiology, 48(1), 318–339. https://doi.org/10.1007/s00261-022-03693-0

Kim, H. S., Song, W., Choo, W., Lee, S., Han, Y., Bassi, C., Salvia, R., Marchegiani, G., Wolfgang, C. L., He, J., Blair, A. B., Kluger, M. D., Su, G. H., Kim, S. C., Song, K., Yamamoto, M., Hatori, T., Yang, C., Yamaue, H., … Jang, J. (2021). Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study. Journal of Hepato-Biliary-Pancreatic Sciences, 30(1), 133–143. Portico. https://doi.org/10.1002/jhbp.962

Gartrell, R. D., Enzler, T., Kim, P. S., Fullerton, B. T., Fazlollahi, L., Chen, A. X., Minns, H. E., Perni, S., Weisberg, S. P., Rizk, E. M., Wang, S., Oh, E. J., Guo, X. V., Chiuzan, C., Manji, G. A., Bates, S. E., Chabot, J., Schrope, B., Kluger, M., … Saenger, Y. M. (2022). Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. OncoImmunology, 11(1). https://doi.org/10.1080/2162402x.2022.2066767

Saeki, K., Qiu, W., Friedman, R. A., Pan, S., Lu, J., Ichimiya, S., Chio, I. I. C., Shawber, C. J., Kitajewski, J., Hu, J., & Su, G. H. (2022). Inactivation ofNotch4Attenuated Pancreatic Tumorigenesis in Mice. Cancer Research Communications, 2(12), 1601–1616. https://doi.org/10.1158/2767-9764.crc-22-0106

Curiel-Garcia, A., Decker-Farrell, A. R., Sastra, S. A., & Olive, K. P. (2022). Generation of orthotopic patient-derived xenograft models for pancreatic cancer using tumor slices. STAR Protocols, 3(4), 101899. https://doi.org/10.1016/j.xpro.2022.101899

Thomas, A. S., Kwon, W., Horowitz, D. P., Bates, S. E., Fojo, A. T., Manji, G. A., Schreibman, S., Schrope, B. A., Chabot, J. A., & Kluger, M. D. (2022). Long‐term follow‐up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer. Journal of Surgical Oncology, 126(8), 1442–1450. Portico. https://doi.org/10.1002/jso.27085

Dbouk, M., Katona, B. W., Brand, R. E., Chak, A., Syngal, S., Farrell, J. J., Kastrinos, F., Stoffel, E. M., Blackford, A. L., Rustgi, A. K., Dudley, B., Lee, L. S., Chhoda, A., Kwon, R., Ginsberg, G. G., Klein, A. P., Kamel, I., Hruban, R. H., He, J., … Goggins, M. (2022). The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal of Clinical Oncology, 40(28), 3257–3266. https://doi.org/10.1200/jco.22.00298

Schweber, A. B., Agarunov, E., Brooks, C., Hur, C., & Gonda, T. A. (2022). New-Onset Diabetes Is a Potential Marker for the Malignant Transformation of Pancreatic Cysts. Pancreas, 51(9), 1186–1193. https://doi.org/10.1097/mpa.0000000000002161

Ingram, M. A., Lauren, B. N., Pumpalova, Y., Park, J., Lim, F., Bates, S. E., Kastrinos, F., Manji, G. A., Kong, C. Y., & Hur, C. (2022). Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 5(9). Portico. https://doi.org/10.1002/cnr2.1565

Peters, M. L. B., Eckel, A., Lietz, A., Seguin, C., Mueller, P., Hur, C., & Pandharipande, P. V. (2022). Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. Pancreatology, 22(6), 760–769. https://doi.org/10.1016/j.pan.2022.05.003

He, D., Feng, H., Sundberg, B., Yang, J., Powers, J., Christian, A. H., Wilkinson, J. E., Monnin, C., Avizonis, D., Thomas, C. J., Friedman, R. A., Kluger, M. D., Hollingsworth, M. A., Grandgenett, P. M., Klute, K. A., Toste, F. D., Chang, C. J., & Chio, I. I. C. (2022). Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. Molecular Cell, 82(16), 3045-3060.e11. https://doi.org/10.1016/j.molcel.2022.06.005

Thomas, A. S., Sharma, R. K., Kwon, W., Sugahara, K. N., Chabot, J. A., Schrope, B. A., & Kluger, M. D. (2022). Socioeconomic Predictors of Access to Care for Patients with Operatively Managed Pancreatic Cancer in New York State. Journal of Gastrointestinal Surgery, 26(8), 1647–1662. https://doi.org/10.1007/s11605-022-05320-1

Scales, M. K., Velez-Delgado, A., Steele, N. G., Schrader, H. E., Stabnick, A. M., Yan, W., Mercado Soto, N. M., Nwosu, Z. C., Johnson, C., Zhang, Y., Salas-Escabillas, D. J., Menjivar, R. E., Maurer, H. C., Crawford, H. C., Bednar, F., Olive, K. P., Pasca di Magliano, M., & Allen, B. L. (2022). Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. PLOS Genetics, 18(7), e1010315. https://doi.org/10.1371/journal.pgen.1010315

Kurz, E., Hirsch, C. A., Dalton, T., Shadaloey, S. A., Khodadadi-Jamayran, A., Miller, G., Pareek, S., Rajaei, H., Mohindroo, C., Baydogan, S., Ngo-Huang, A., Parker, N., Katz, M. H. G., Petzel, M., Vucic, E., McAllister, F., Schadler, K., Winograd, R., & Bar-Sagi, D. (2022). Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell, 40(7), 720-737.e5. https://doi.org/10.1016/j.ccell.2022.05.006

Thomas, A. S., Huang, Y., Kwon, W., Schrope, B. A., Sugahara, K., Chabot, J. A., Wright, J. D., & Kluger, M. D. (2022). Prevalence and Risk Factors for Pancreatic Insufficiency After Partial Pancreatectomy. Journal of Gastrointestinal Surgery, 26(7), 1425–1435. https://doi.org/10.1007/s11605-022-05302-3

Park, J., Artin, M. G., Lee, K. E., Pumpalova, Y. S., Ingram, M. A., May, B. L., Park, M., Hur, C., & Tatonetti, N. P. (2022). Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer. Journal of Biomedical Informatics, 131, 104095. https://doi.org/10.1016/j.jbi.2022.104095

Verginadis, I. I., Avgousti, H., Monslow, J., Skoufos, G., Chinga, F., Kim, K., Leli, N. M., Karagounis, I. V., Bell, B. I., Velalopoulou, A., Salinas, C. S., Wu, V. S., Li, Y., Ye, J., Scott, D. A., Osterman, A. L., Sengupta, A., Weljie, A., Huang, M., … Koumenis, C. (2022). A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nature Cell Biology, 24(6), 940–953. https://doi.org/10.1038/s41556-022-00918-8

Thomas, A. S., Luk, L., & Chabot, J. A. (2022). Natural History of Pancreatic Duct Obstruction by a Pancreatic Neuroendocrine Tumor. Journal of Gastrointestinal Surgery, 26(6), 1340–1341. https://doi.org/10.1007/s11605-022-05257-5

Li, S., Silvestri, V., Leslie, G., Rebbeck, T. R., Neuhausen, S. L., Hopper, J. L., Nielsen, H. R., Lee, A., Yang, X., McGuffog, L., Parsons, M. T., Andrulis, I. L., Arnold, N., Belotti, M., Borg, Å., Buecher, B., Buys, S. S., Caputo, S. M., Chung, W. K., … Antoniou, A. C. (2022). Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 40(14), 1529–1541. https://doi.org/10.1200/jco.21.02112

Zylberberg, H. M., Woodrell, C., Rustgi, S. D., Aronson, A., Kessel, E., Amin, S., & Lucas, A. L. (2022). Opioid Prescription Is Associated With Increased Survival in Older Adult Patients With Pancreatic Cancer in the United States: A Propensity Score Analysis. JCO Oncology Practice, 18(5), e659–e668. https://doi.org/10.1200/op.21.00488

Zylberberg, H. M., Nagula, S., Rustgi, S. D., Aronson, A., Kessel, E., Kumta, N. A., DiMaio, C. J., & Lucas, A. L. (2022). Celiac Plexus Neurolysis Is Associated With Decreased Survival in Patients With Pancreatic Cancer. Pancreas, 51(2), 153–158. https://doi.org/10.1097/mpa.0000000000001992

Chhoda, A., Vodusek, Z., Wattamwar, K., Mukherjee, E., Gunderson, C., Grimshaw, A., Sharma, A., Ahuja, N., Kastrinos, F., & Farrell, J. J. (2022). Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology, 162(3), 786–798. https://doi.org/10.1053/j.gastro.2021.11.021

Overbeek, K. A., Goggins, M. G., Dbouk, M., Levink, I. J. M., Koopmann, B. D. M., Chuidian, M., Konings, I. C. A. W., Paiella, S., Earl, J., Fockens, P., Gress, T. M., Ausems, M. G. E. M., Poley, J.-W., Thosani, N. C., Half, E., Lachter, J., Stoffel, E. M., Kwon, R. S., Stoita, A., … Bruno, M. J. (2022). Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology, 162(3), 772-785.e4. https://doi.org/10.1053/j.gastro.2021.10.014

Yan, H., Yu, C.-C., Fine, S. A., Youssof, A. L., Yang, Y.-R., Yan, J., Karg, D. C., Cheung, E. C., Friedman, R. A., Ying, H., Chen, E. I., Luo, J., Miao, Y., Qiu, W., & Su, G. H. (2021). Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Oncogene, 40(50), 6759–6771. https://doi.org/10.1038/s41388-021-02040-9

Schweber, A. B., Agarunov, E., Brooks, C., Hur, C., & Gonda, T. A. (2021). Prevalence, Incidence, and Risk of Progression of Asymptomatic Pancreatic Cysts in Large Sample Real-world Data. Pancreas, 50(9), 1287–1292. https://doi.org/10.1097/mpa.0000000000001918

Kremer, D. M., Nelson, B. S., Lin, L., Yarosz, E. L., Halbrook, C. J., Kerk, S. A., Sajjakulnukit, P., Myers, A., Thurston, G., Hou, S. W., Carpenter, E. S., Andren, A. C., Nwosu, Z. C., Cusmano, N., Wisner, S., Mbah, N. E., Shan, M., Das, N. K., Magnuson, B., … Lyssiotis, C. A. (2021). GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-24859-2

Rustgi, S. D., Hilfrank, K. J., & Kastrinos, F. (2022). Familial Predisposition and Genetic Risk Factors Associated with Pancreatic Cancer. Gastrointestinal Endoscopy Clinics of North America, 32(1), 1–12. https://doi.org/10.1016/j.giec.2021.09.001

Katona, B. W., Long, J. M., Ahmad, N. A., Attalla, S., Bradbury, A. R., Carpenter, E. L., Clark, D. F., Constantino, G., Das, K. K., Domchek, S. M., Dudzik, C., Ebrahimzadeh, J., Ginsberg, G. G., Heiman, J., Kochman, M. L., Maxwell, K. N., McKenna, D. B., Powers, J., Shah, P. D., … Rustgi, A. K. (2021). EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Cancer Prevention Research, 14(11), 1033–1040. https://doi.org/10.1158/1940-6207.capr-21-0161

Ager, C. R., Boda, A., Rajapakshe, K., Lea, S. T., Di Francesco, M. E., Jayaprakash, P., Slay, R. B., Morrow, B., Prasad, R., Dean, M. A., Duffy, C. R., Coarfa, C., Jones, P., & Curran, M. A. (2021). High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Journal for ImmunoTherapy of Cancer, 9(8), e003246. https://doi.org/10.1136/jitc-2021-003246